Melflufen for the treatment of multiple myeloma

Author:

Ocio Enrique M.1ORCID,Nadeem Omar2,Schjesvold Fredrik3,Gay Francesca4,Touzeau Cyrille5,Dimopoulos Meletios A.6ORCID,Richardson Paul G.2,Mateos Maria-Victoria7ORCID

Affiliation:

1. Department of Hematology, University Hospital Marqués de Valdecilla (IDIVAL), University of CantabriaUniversity Hospital Marqués de Valdecilla (IDIVAL), University of Cantabria, Santander, Spain

2. Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA

3. Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway

4. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

5. Hematology Department, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Université d’Angers, Université de Nantes, Nantes, France; Site de Recherche Intégrée sur le Cancer (SIRIC), Imaging and Longitudinal Investigations to Ameliorate Decision-making (ILIAD), Nantes, France; Service d’hématologie Clinique, Centre Hospitalier Universitaire, Place Alexis...

6. Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

7. Department of Haematology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Reference68 articles.

1. Cancer Statistics, 2021

2. Global Burden of Multiple Myeloma

3. National Cancer Institute Surveillance E and end result program. cancer stat facts: myeloma 2022 [2022 Feb 28]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html

4. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd

5. Multiple myeloma

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3